| Dr Marcus Lejon Williams, MD | |
|
10666 N Torrey Pines Road, La Jolla, CA 92037-1027 | |
| (858) 554-5257 | |
| Not Available |
| Full Name | Dr Marcus Lejon Williams |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 23 Years |
| Location | 10666 N Torrey Pines Road, La Jolla, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417026436 | NPI | - | NPPES |
| 854728375A | Medicaid | GA | |
| J005 | Other | CA | CHAMPUS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 054048 (Georgia) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | A98711 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar West Georgia Medical Center | Lagrange, GA | Hospital |
| Emory University Hospital | Atlanta, GA | Hospital |
| Tift Regional Medical Center | Tifton, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emory Specialty Associates, Llc | 3476559782 | 430 |
| Tift Regional Health System Inc | 2062745169 | 298 |
News Archive
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.
Landec Corporation, today reported results for the second quarter and first half of fiscal year 2012. Revenues for the second quarter of fiscal year 2012 increased 16% to $81.6 million compared to revenues of $70.2 million for the second quarter of fiscal year 2011.
The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
› Verified 2 days ago
| Entity Name | Tift Regional Health System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790280857 PECOS PAC ID: 5193619971 Enrollment ID: O20040212000064 |
News Archive
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.
Landec Corporation, today reported results for the second quarter and first half of fiscal year 2012. Revenues for the second quarter of fiscal year 2012 increased 16% to $81.6 million compared to revenues of $70.2 million for the second quarter of fiscal year 2011.
The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
› Verified 2 days ago
| Entity Name | Coffee Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437120946 PECOS PAC ID: 4587656012 Enrollment ID: O20040402000287 |
News Archive
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.
Landec Corporation, today reported results for the second quarter and first half of fiscal year 2012. Revenues for the second quarter of fiscal year 2012 increased 16% to $81.6 million compared to revenues of $70.2 million for the second quarter of fiscal year 2011.
The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
› Verified 2 days ago
| Entity Name | Emory Specialty Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407864168 PECOS PAC ID: 3476559782 Enrollment ID: O20061010000447 |
News Archive
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.
Landec Corporation, today reported results for the second quarter and first half of fiscal year 2012. Revenues for the second quarter of fiscal year 2012 increased 16% to $81.6 million compared to revenues of $70.2 million for the second quarter of fiscal year 2011.
The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
› Verified 2 days ago
| Entity Name | Tift Regional Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881203305 PECOS PAC ID: 2062745169 Enrollment ID: O20200217002409 |
News Archive
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.
Landec Corporation, today reported results for the second quarter and first half of fiscal year 2012. Revenues for the second quarter of fiscal year 2012 increased 16% to $81.6 million compared to revenues of $70.2 million for the second quarter of fiscal year 2011.
The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marcus Lejon Williams, MD File # 54433, Los Angeles, CA 90074-0001 Ph: () - | Dr Marcus Lejon Williams, MD 10666 N Torrey Pines Road, La Jolla, CA 92037-1027 Ph: (858) 554-5257 |
News Archive
A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.
Landec Corporation, today reported results for the second quarter and first half of fiscal year 2012. Revenues for the second quarter of fiscal year 2012 increased 16% to $81.6 million compared to revenues of $70.2 million for the second quarter of fiscal year 2011.
The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
› Verified 2 days ago
Dr. John Sturdivant Andrews, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1223 Via Barranca, La Jolla, CA 92037 Phone: 858-775-1976 | |
Dr. Mark C Adrian, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9850 Genesee Ave, Suite 355, La Jolla, CA 92037 Phone: 858-202-0011 | |
Dr. Erminia M. Guarneri, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-3330 Fax: 858-784-5933 | |
Dr. Eric Hong, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9834 Genesee Ave, Suite 300, La Jolla, CA 92037 Phone: 858-824-2900 Fax: 858-824-2910 | |
Katrina Deleon, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-6158 | |
Abhishek Gadre, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-657-7118 | |
Kamran Hussain Imam, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-6158 |